New York, Feb 2, 2026, 15:08 (ET) — Regular session
- BSX dropped roughly 1.6% in afternoon trading, underperforming the stronger broader market
- TD Cowen highlighted Watchman’s CHAMPION-AF trial results expected in late March as a crucial catalyst
- Investors are gearing up ahead of Boston Scientific’s earnings call on Feb. 4
Boston Scientific shares dropped roughly 1.6% to $92.01 in Monday afternoon trading, bouncing between $94.13 and $91.64 earlier. The stock underperformed peers Abbott Laboratories, Medtronic Plc, and Stryker Corp., even as the S&P 500 ETF Trust (SPDR S&P 500 ETF) climbed higher.
Timing is key. Boston Scientific will hold a conference call Wednesday, Feb. 4 at 8:00 a.m. ET to review its fourth-quarter financials—a crucial moment to recalibrate forecasts for growth and margins ahead of 2026. investors.bostonscientific.com
Another key date: the CHAMPION-AF trial’s primary results will be revealed on March 28 at the American College of Cardiology’s ACC.26 event in New Orleans, per the conference schedule. accscientificsession.acc.org
TD Cowen’s Josh Jennings stuck with a buy rating and a $115 price target on Monday, saying the CHAMPION-AF data isn’t fully priced in yet, according to TipRanks. He pointed out that the trial’s endpoints mirror those from the earlier OPTION study, which could expand the patient pool if Watchman proves viable as a first-line alternative to blood thinners. TipRanks
CHAMPION-AF is investigating left atrial appendage closure (LAAC), an implant technique designed to lower stroke risk in atrial fibrillation, against long-term blood thinner therapy. Boston Scientific says the trial aims to see if its WATCHMAN FLX device can serve as a first-line alternative to anticoagulants for certain patients. www.bostonscientific.com
A clinical trial listing states the study’s primary objective is to assess if LAAC with WATCHMAN FLX can serve as a viable alternative to direct oral anticoagulants (DOACs), widely used blood thinners. ClinicalTrials.gov
The near-term outlook is tricky. A disappointing Feb. 4 forecast from Boston Scientific, or underwhelming CHAMPION-AF results on safety or efficacy, could force the market to rethink growth prospects for Watchman and the wider cardiovascular unit.
Traders are focused on Wednesday’s results call, looking for any change in the 2026 outlook. Beyond that, the March 28 CHAMPION-AF presentation at ACC.26 stands as the next clear catalyst.
